GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nexien BioPharma Inc (OTCPK:NXEN) » Definitions » Debt-to-Equity

Nexien BioPharma (Nexien BioPharma) Debt-to-Equity : -0.75 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Nexien BioPharma Debt-to-Equity?

Nexien BioPharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.24 Mil. Nexien BioPharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Nexien BioPharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-0.31 Mil. Nexien BioPharma's debt to equity for the quarter that ended in Dec. 2023 was -0.75.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Nexien BioPharma's Debt-to-Equity or its related term are showing as below:

NXEN' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.37   Med: -0.96   Max: 0.38
Current: -0.75

During the past 7 years, the highest Debt-to-Equity Ratio of Nexien BioPharma was 0.38. The lowest was -2.37. And the median was -0.96.

NXEN's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.29 vs NXEN: -0.75

Nexien BioPharma Debt-to-Equity Historical Data

The historical data trend for Nexien BioPharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexien BioPharma Debt-to-Equity Chart

Nexien BioPharma Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Equity
Get a 7-Day Free Trial - -2.00 -0.93 -1.88 -1.08

Nexien BioPharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.05 -0.96 -1.08 -0.80 -0.75

Competitive Comparison of Nexien BioPharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Nexien BioPharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nexien BioPharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nexien BioPharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Nexien BioPharma's Debt-to-Equity falls into.


Nexien BioPharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Nexien BioPharma's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.271 + 0) / -0.252
=-1.08

Nexien BioPharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.235 + 0) / -0.314
=-0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexien BioPharma  (OTCPK:NXEN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Nexien BioPharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Nexien BioPharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nexien BioPharma (Nexien BioPharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nexien BioPharma Inc (OTCPK:NXEN) » Definitions » Debt-to-Equity
Comparable Companies
CSUI AKAN GPFT KAYS SBFM BSPK LSDI MCIC ACORQ INQD ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX
Traded in Other Exchanges
N/A
Address
4340 East Kentucky Avenue, Suite 206, Glendale, CO, USA, 80246
Website
https://www.nexienbiopharma.com
Nexien BioPharma Inc is a researcher and developer of cannabinoid-based pharmaceutical for various medical conditions and disorders, all under U.S. Food and Drug Administration development pathways.
Executives
Jeffrey Friedland other: Former 10% Owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Kanativa Usa Inc. 10 percent owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Kanativa Inc. 10 percent owner 4340 E. KENTUCKY AVE., SUITE 206, GLENDALE CO 80246
Joseph F Aceto officer: VP Legal & IP Counsel 1617 NEWARK ROAD, KENNETT SQUARE PA 19348
Jeremy Robert Reeh officer: VP Translational Research 11 TANKARD LANE, WASHINGTON CROSSING PA 18977
Alexander Michael Wasyl director, officer: Chief Executive Officer 31 BEIDLER DRIVE, WASHINGTON CROSSING PA 18977
Frank J Manganella officer: VP Corporate Development 148-26 10TH AVENUE, WHITESTONE NY 11357
Clark Courtney Lynne director PO BOX 7801, ASPEN CO 81612
Lindy Snider director 408 BARBARA LANE, BRYN MAWR PA 19010
Robert I Goldfarb officer: Chief Operating Officer 230 GOLDEN BEACH DRIVE, GOLDEN BEACH FL 33160
Evan L Wasoff officer: Chief Financial Officer 101 WINGER DRIVE, NEDERLAND CO 80466
Alain D Bankier director 150 COLUMBUS AVENUE APT 17F, NEW YORK NY 10023
Richard S Greenberg director, 10 percent owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Ivo Heiden director, 10 percent owner 2275 HUNTINGTON DRIVE, SUITE 851, SAN MARINO CA 91108